Research and development for new tools to treat, diagnose and prevent tuberculosis (TB) is moving forward far too slowly, according to a report published by Treatment Action Group (TAG) and HIV i-Base.
The 2013 Pipeline Report identifies some successes in the development and deployment of new tools to fight TB, but says that a lack of investment and political will has resulted in a pipeline for new TB diagnostics, treatments and vaccines that is anaemic when compared to those for HIV and Hepatitis C Virus (HCV).
To speed up the delivery of the best medical products to tackle HIV, HCV and TB, the report’s authors call on research funders to continue investing in better products, demand that regulators expedite the review of new medications and call on international and national authorities to continue to streamline and simplify treatment guidelines, among other recommendations.
Read the full report
Comments are closed.